- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.60 Å
- Oligo State
- homo-trimer
- Ligands
- 3 x ZN: ZINC ION
- 3 x 01: (3S)-3-(3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-1-yl)piperidine-2,6-dione
01.2: 8 residues within 4Å:- Chain A: E.63, H.64, S.65, W.66, W.72, W.86, F.88
- Ligands: EDO.5
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:W.72, A:W.72, A:W.72, A:W.86
- Hydrogen bonds: A:H.64, A:W.66
01.9: 9 residues within 4Å:- Chain B: E.63, H.64, S.65, W.66, W.72, W.86, F.88
- Ligands: EDO.11, EDO.13
8 PLIP interactions:8 interactions with chain B- Hydrophobic interactions: B:E.63, B:W.66, B:W.72, B:W.72, B:W.72, B:W.86
- Hydrogen bonds: B:H.64, B:W.66
01.18: 8 residues within 4Å:- Chain C: E.63, H.64, S.65, W.66, W.72, W.86, F.88
- Ligands: EDO.21
7 PLIP interactions:7 interactions with chain C- Hydrophobic interactions: C:W.66, C:W.72, C:W.72, C:W.72, C:W.86
- Hydrogen bonds: C:H.64, C:W.66
- 5 x SO4: SULFATE ION
SO4.3: 6 residues within 4Å:- Chain A: K.50, K.87, K.99, W.101
- Chain B: P.97, Q.98
7 PLIP interactions:5 interactions with chain A, 2 interactions with chain B- Water bridges: A:K.50, A:W.101
- Salt bridges: A:K.50, A:K.87, A:K.99
- Hydrogen bonds: B:Q.98, B:K.99
SO4.4: 7 residues within 4Å:- Chain A: P.97, Q.98, K.99
- Chain C: K.50, K.87, K.99, W.101
9 PLIP interactions:7 interactions with chain C, 2 interactions with chain A- Water bridges: C:K.50, C:K.50, C:A.51, C:K.99
- Salt bridges: C:K.50, C:K.87, C:K.99
- Hydrogen bonds: A:Q.98, A:K.99
SO4.10: 5 residues within 4Å:- Chain A: K.50
- Chain B: K.50, K.99
- Chain C: K.50, K.99
8 PLIP interactions:4 interactions with chain B, 1 interactions with chain A, 3 interactions with chain C- Water bridges: B:K.50, B:K.99, C:K.50, C:K.50
- Salt bridges: B:K.50, B:K.99, A:K.50, C:K.50
SO4.19: 7 residues within 4Å:- Chain B: K.50, K.87, K.99, W.101
- Chain C: S.96, P.97, Q.98
8 PLIP interactions:6 interactions with chain B, 2 interactions with chain C- Water bridges: B:K.50, B:K.87, B:K.87, C:M.95
- Salt bridges: B:K.50, B:K.87, B:K.99
- Hydrogen bonds: C:Q.98
SO4.20: 1 residues within 4Å:- Chain C: H.64
3 PLIP interactions:3 interactions with chain C- Water bridges: C:H.64, C:H.64
- Salt bridges: C:H.64
- 10 x EDO: 1,2-ETHANEDIOL
EDO.5: 4 residues within 4Å:- Chain A: W.72, V.74, W.86
- Ligands: 01.2
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:W.86
EDO.6: 4 residues within 4Å:- Chain A: E.16
- Chain B: I.23, F.24, S.25
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:I.23
EDO.7: 5 residues within 4Å:- Chain A: S.6, C.8, E.14, E.16
- Chain B: S.25
4 PLIP interactions:3 interactions with chain A, 1 interactions with chain B- Hydrogen bonds: A:S.6
- Water bridges: A:E.14, A:E.14, B:S.25
EDO.11: 5 residues within 4Å:- Chain B: W.72, V.74, H.83, W.86
- Ligands: 01.9
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:W.86
EDO.12: 2 residues within 4Å:- Chain B: H.43, E.44
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:H.43, B:H.43
EDO.13: 4 residues within 4Å:- Chain B: W.66, W.86
- Ligands: 01.9, EDO.14
No protein-ligand interaction detected (PLIP)EDO.14: 4 residues within 4Å:- Chain B: E.44, T.104, S.106
- Ligands: EDO.13
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:E.44, B:E.44, B:S.106
- Water bridges: B:S.106
EDO.15: 6 residues within 4Å:- Chain B: T.5, E.16, T.19
- Chain C: I.23, F.24, S.25
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:E.16
EDO.16: 6 residues within 4Å:- Chain B: F.24, S.25, L.26, V.42, T.45, T.47
5 PLIP interactions:5 interactions with chain B- Hydrogen bonds: B:F.24, B:L.26, B:V.42, B:T.47
- Water bridges: B:T.47
EDO.21: 4 residues within 4Å:- Chain C: W.72, V.74, W.86
- Ligands: 01.18
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:W.86
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Zheng, X. et al., Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases. J.Med.Chem. (2024)
- Release Date
- 2024-08-28
- Peptides
- Protein cereblon: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
DB
EC
F
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.60 Å
- Oligo State
- homo-trimer
- Ligands
- 3 x ZN: ZINC ION
- 3 x 01: (3S)-3-(3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-1-yl)piperidine-2,6-dione
- 5 x SO4: SULFATE ION
- 10 x EDO: 1,2-ETHANEDIOL
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Zheng, X. et al., Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases. J.Med.Chem. (2024)
- Release Date
- 2024-08-28
- Peptides
- Protein cereblon: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
DB
EC
F